Form 4: Nautilus Biotechnology CEO Sujal Patel Increases Stake in Company

Nautilus Biotechnology's CEO, Sujal Patel, recently acquired additional shares of the company's common stock through direct purchases.

Summary

• On March 19, 2025, Sujal Patel, the CEO, President, and Secretary of Nautilus Biotechnology, purchased 53,300 shares of common stock at a weighted average price of $0.9949.
• The prices for these shares ranged from $0.9469 to $1.10.
• Following this transaction, Patel directly owns 10,117,788 shares.
• On March 20, 2025, Patel purchased an additional 23,933 shares at a weighted average price of $0.9982, with prices ranging from $0.9351 to $1.06.
• Following this transaction, Patel directly owns 10,141,721 shares.
• Patel also indirectly owns 1,814,035 shares through the Sujal Patel 2020 Children's Trust and 5,280,476 shares through PFV I, LLC.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. The CEO's purchase of shares is a positive sign, but it's a routine transaction disclosure.

Positives

• The CEO's purchase of shares could be interpreted as a positive signal, indicating confidence in the company's future prospects.

Industry Context

Insider buying is often monitored by investors as an indicator of management's confidence in the company's prospects. It can be a positive signal, especially when a CEO increases their stake.

Key Dates

Keywords

Nautilus Biotechnology, Sujal Patel, insider trading, share purchase, common stock, ownership